Repositorio
Institucional

Eikelboom, John W.

Bosch, Jacqueline

Connolly, Stuart J.

Tyrwitt, Jessica

Fox, Keith A. A.

Muehlhofer, Eva

Neumann, Christoph

Tasto, Christoph

Bangdiwala, Shrikant

Diaz, Rafael

Alings, Marco

Dagenais, Gilles R.

Leong, Darryl P.

Lonn, Eva M.

Avezum, Alvaro

Piegas, Leopoldo S.

Widimsky, Petr

Parkhomenko, Alexander N.

Bhatt, Deepak L.

Branch, Kelley R. H.

Probstfield, Jeffrey L.

Lopez-Jaramillo, Patricio

Ryden, Lars

Pogosova, Nana

Keltai, Katalin

Keltai, Matyas

Ertl, Georg

Stoerk, Stefan

Dans, Antonio L.

Lanas, Fernando

Liang, Yan

Zhu, Jun

Torp-Pedersen, Christian

Maggioni, Aldo P.

Commerford, Patrick J.

Guzik, Tomasz J.

Vanassche, Thomas

Verhamme, Peter

O'Donnell, Martin

Tonkin, Andrew M.

Varigos, John D.

Vinereanu, Dragos

Felix, Camillo

Kim, Jae-Hyung

Ibrahim, Khairul S.

Lewis, Basil S.

Metsarinne, Kaj P.

Aboyans, Victor

Steg, Phillippe Gabriel

Hori, Masatsugu

Kakkar, Ajay

Anand, Sonia S.

Lamy, Andre

Sharma, Mukul

Yusuf, Salim

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

OXFORD UNIV PRESS

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY

en

Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE). Methods and results Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination. Conclusion In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.

2022

artículo original

acceso abierto

10.1093/ehjcvp/pvac023

PDF

Coronary artery disease

Peripheral artery disease

Aspirin

Rivaroxaban

Sistema cardiovascular y cardiología

Farmacología y farmacia

Sistema Cardiovascular y Cardiaco

Farmacología y Farmacia

Arteriopatía coronaria

Enfermedad de las arterias periféricas

Aspirina

Rivaroxabán

786.0

795

artículo original

versión publicada

acceso abierto

acceso abierto

WOS:000805292700001

2055-6837

verde# dorado

Sistema cardiovascular y cardiología

Farmacología y farmacia